Volume 13, Issue 1, Pages (January 2006)

Slides:

Advertisements

Similar presentations

Gene Preference in Maple Syrup Urine Disease Mary M. Nellis, Dean J. Danner The American Journal of Human Genetics Volume 68, Issue 1, Pages (January.

Advertisements

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Design and Multiseries Validation of a Web-Based Gene Expression Assay for Predicting Breast Cancer Recurrence and Patient Survival Ryan K. Van Laar The.

Volume 164, Issue 6, Pages (December 2000)

Volume 20, Issue 2, (February 2012)

Managing Metastatic Bone Pain: The Role of Bisphosphonates

209. Use of Helicobacter pyroli Neutrophil Activating Protein (NAP) as an Immune- Modulatory Agent To Enhance the Efficacy of Oncolytic Adenovirus Therapy.

Managing Metastatic Bone Pain: The Role of Bisphosphonates

Genome-editing Technologies for Gene and Cell Therapy

627. Non-Invasive, Multimodal Imaging of Microvesicles with Metabolically Biotinylated, Membrane-Bound Gaussia Luciferase Molecular Therapy Volume.

162. Stability of Polymer/Plasmid DNA Complexes In Vitro and In Vivo

281. Rapid Generation of Induced Pluripotent Stem Cells (iPSCs) from the Urine of a Patient with Duchenne Muscular Dystrophy Molecular Therapy Volume.

Dr L. S. Kim, N. D. , Dr L. J. Axelrod, N. D. , Dr P. Howard, M. D

R. Cantón Clinical Microbiology and Infection

Sara A. Farber, BA, Sara Samimi, MD, Misha Rosenbach, MD

Molecular Therapy Volume 20, Pages S261-S262 (May 2012) DOI: /S (16)

Volume 25, Issue 10, Pages (October 2017)

2016 Curt Stern Award Address: From Rare to Common Diseases: Translating Genetic Discovery to Therapy1 Brendan Lee The American Journal of Human Genetics

Evolving Gene Therapy in Primary Immunodeficiency

Volume 26, Issue 2, Pages (February 2018)

New HCV therapies on the horizon

Myoblast Transplantation for Cardiac Repair: A Clinical Perspective

Volume 25, Issue 1, Pages 5-7 (January 2017)

Xiuyan Wang, Isabelle Rivière Molecular Therapy - Oncolytics

Volume 25, Issue 5, Pages (May 2017)

The Other Face of Chimeric Antigen Receptors

Levofloxacin in the treatment of ventilator-associated pneumonia

724. Blood-Derived Endothelial Progenitor Cells Can Be Isolated With a Novel Method of Diluted Whole Blood Incubation with AMD3100-Induced Mobilization.

Genome-editing Technologies for Gene and Cell Therapy

Premal Lulla, Carlos A. Ramos Molecular Therapy

Molecular Therapy Volume 20, (May 2012) DOI: /S (16)

Molecular Therapy Volume 7, Issue 5, (May 2003) DOI: /S (16)

847. Eradication of Therapy-Resistant Human Prostate Tumors Using an Ultrasound Guided Site-Specific Cancer Terminator Virus Delivery Approach Molecular.

Volume 25, Issue 5, Pages (May 2017)

133. Survival with Normal Neurological Development of the Juvenile Lethal Urea Cycle Defect Arginase Deficient Mouse with AAV Gene Therapy Molecular.

Erratum The American Journal of Human Genetics

Accurate hepatitis C virus genotyping and selection of optimal therapy: lessons from a St Petersburg strain infection E. Knops, E. Heger Clinical Microbiology.

660. Bowel/Bladder Sensation and Control in Patients with Spinal Cord Injury Treated with Human Embryonic Stem Cell Therapy Geeta Shroff Molecular Therapy

Volume 26, Issue 2, Pages (February 2018)

68. Site Specific Intra-Placental Gene Transfer Corrects Fetal Growth Restriction in a Novel Mouse Model of Placental Insufficiency (PI) Molecular.

521. Multiplex Genome Editing of TCR°/CD52 Genes as a Platform for “Off the Shelf” Adoptive T-Cell Immunotherapies Molecular Therapy Volume 22, Pages.

Study Designs in Patient-Oriented Research

Volume 13, Pages S217-S218 (January 2006)

Volume 17, Issue 2, Pages (February 1950)

Alan J. Nixon, Christina W. Cheng, Lisa Strassheim, Paul D. Robbins

Volume 14, Issue 1, Pages (July 2006)

Volume 26, Issue 4, Pages (April 2018)

Establishing Polymeric Transfection as a Non-Viral, Non-Toxic Method for Gene Therapy in the Prevention of Vascular Disease Joshua D. Arnold, Deidra.

674. Molecular, Biochemical and Biomechanical Analysis of Articular Cartilage Repaired with Genetically Modified Chondrocytes Expressing Insulin-Like.

287. Improved Outcomes Following Drug-Resistant Immunotherapy in a Human Xenograft Model of Temozolomide-Resistant Glioblastoma Multiforme Harold T.

Molecular Therapy Volume 18, Pages S260-S261 (May 2010) DOI: /S (16)

In This Issue Molecular Therapy Volume 16, Issue 4, (April 2008)

521. AAV Immunotherapy Induces Functional Antigen Specific Regulatory T-Cells to a Neuroantigen: A Potential Treatment for MS Brad E. Hoffman Molecular.

Oncolytic Virotherapy: A Contest between Apples and Oranges

773. Detection of RNA Interference (RNAi) Mediated mRNA Cleavage in Fresh Injected Tumor Tissue from Patients in a Phase I Trial of pbi-shRNA™ Lipoplex.

Cardiovascular surgery—The rocket and its stars: Presidential address

740. Prevention of Radiation-Induced Lung Injury by Administration of Gene-Modified Mesenchymal Stem Cells Molecular Therapy Volume 20, Pages S285-S286.

Molecular Therapy Volume 21, Pages S247-S248 (May 2013)

Vanadium: A Panacea for Resistance to Oncolytic Immunotherapy?

History of Oncolytic Viruses: Genesis to Genetic Engineering

86. A Highly Compact Epitope-Based Marker Suicide Gene for Safer and Easier Adoptive T-Cell Gene Therapy Molecular Therapy Volume 20, Pages S35-S36.

Treatment versus Transplant for Challenging Hematologic Disorders

Thomas N. Ahlborn, M.D., John D. Birkhoff, M.D., Roman Nowygrod, M.D.

Volume 26, Issue 5, Pages (May 2018)

Appropriate Use Criteria for coronary revascularization in patients with stable ischemic heart disease: What the surgeon needs to know Harold L. Lazar,

Zhijian Wu, Aravind Asokan, R. Jude Samulski Molecular Therapy

Bryan Baillis, MD, John C. Maize, MD JAAD Case Reports

The Propranolol Aneurysm Trial Investigators

Volume 10, Issue 5, Pages (November 2004)

624. Randomized Phase II Trial of Adjuvant Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer: Preliminary Results Molecular.

Presentation transcript:

Volume 13, Issue 1, Pages 221-228 (January 2006) Phase I/II Trial of Intravenous NDV-HUJ Oncolytic Virus in Recurrent Glioblastoma Multiforme Arnold I. Freeman, Zichria Zakay-Rones, John M. Gomori, Eduard Linetsky, Linda Rasooly, Evgeniya Greenbaum, Shira Rozenman- Yair, Amos Panet, Eugene Libson, Charles S. Irving, Eithan Galun, Tali Siegal Molecular Therapy Volume 13, Issue 1, Pages 221-228 (January 2006) DOI: 10.1016/j.ymthe.2005.08.016 Copyright © 2005 The American Society of Gene Therapy Terms and Conditions

FIG. 1 Patient enrollment. Molecular Therapy 2006 13, 221-228DOI: (10.1016/j.ymthe.2005.08.016) Copyright © 2005 The American Society of Gene Therapy Terms and Conditions

FIG. 2 Complete tumor response. (A) Patient 09 at baseline, (B) stable disease at first follow-up, (C) partial response (PR) at second follow-up, (D) PR at 20 weeks from start of virotherapy, and (E and F) complete response at 25 and 30 weeks from start of virotherapy. Molecular Therapy 2006 13, 221-228DOI: (10.1016/j.ymthe.2005.08.016) Copyright © 2005 The American Society of Gene Therapy Terms and Conditions

Supplementary Fig. 1 Molecular Therapy 2006 13, 221-228DOI: (10.1016/j.ymthe.2005.08.016) Copyright © 2005 The American Society of Gene Therapy Terms and Conditions